中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
1,2-二溴丙烷 | 1,2-Dibromopropane | 78-75-1 | C3H6Br2 | 201.889 |
中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
1,1,2,3-四溴丙烷 | 1,1,2,3-tetrabromo-propane | 34581-76-5 | C3H4Br4 | 359.681 |
The effect of erdosteine, a mucoactive drug, on hypochlorous acid (HOCl)-induced lung injury, and the lipopolysaccharide (LPS)-induced increase in tumour necrosis factor-α (TNF-α) production and neutrophil recruitment into the airway, was investigated.
Male BALB/c mice were orally administered erdosteine (3–100 mg kg−1), ambroxol hydrochloride (ambroxol) (3–30 mg kg−1), S-carboxymethyl-L-cysteine (S-CMC) (100–600 mg kg−1) or prednisolone (10 mg kg−1), 1h before intratracheal injection of HOC1 or LPS. In the HOCl-injected mice, erdosteine markedly suppressed increases in the ratios of lung wet weight to bodyweight and lung dry weight to bodyweight, whereas the other mucoactive drugs ambroxol and S-CMC had little effect. Erdosteine also inhibited the LPS-induced neutrophil influx, although it did not affect the increased level of TNF-α in the bronchoalveolar lavage fluid.
The results suggest that attenuation of reactive oxygen species and neutrophil recruitment is involved in the clinical efficacy of erdosteine in the treatment of chronic bronchitis.
本研究探讨了黏液活性药物Erdosteine对次氯酸(HOCl)诱导的肺损伤以及脂多糖(LPS)诱导的肿瘤坏死因子-α(TNF-α)产生和中性粒细胞进入气道的影响。
在给BALB/c雄性小鼠口服Erdosteine(3-100 mg/kg)、盐酸氨溴索(Ambroxol)(3-30 mg/kg)、S-羧甲基-L-半胱氨酸(S-CMC)(100-600 mg/kg)或泼尼松龙(10 mg/kg)后1小时,注射HOC1或LPS。在注射HOCl的小鼠中,Erdosteine显著抑制了肺湿重与体重比和肺干重与体重比的增加,而其他黏液活性药物Ambroxol和S-CMC几乎没有效果。Erdosteine还抑制了LPS诱导的中性粒细胞浸润,但并不影响支气管肺泡灌洗液中TNF-α水平的增加。
结果表明,减轻活性氧和中性粒细胞浸润参与了Erdosteine治疗慢性支气管炎的临床疗效。